NASDAQ:GTBP GT Biopharma (GTBP) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free GTBP Stock Alerts $3.65 -0.13 (-3.44%) (As of 12:24 PM ET) Add Compare Share Share Today's Range$3.65▼$3.8350-Day Range$3.65▼$5.0752-Week Range$3.52▼$16.11Volume3,942 shsAverage Volume11,726 shsMarket Capitalization$5.04 millionP/E RatioN/ADividend YieldN/APrice Target$150.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get GT Biopharma alerts: Email Address GT Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,009.6% Upside$150.00 Price TargetShort InterestHealthy0.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.99 out of 5 stars 3.5 Analyst's Opinion Consensus RatingGT Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGT Biopharma has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.71% of the float of GT Biopharma has been sold short.Short Interest Ratio / Days to CoverGT Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GT Biopharma has recently increased by 79.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGT Biopharma does not currently pay a dividend.Dividend GrowthGT Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GTBP. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for GTBP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GT Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of GT Biopharma is held by insiders.Percentage Held by InstitutionsOnly 8.15% of the stock of GT Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GT Biopharma is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GT Biopharma is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGT Biopharma has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About GT Biopharma Stock (NASDAQ:GTBP)GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Read More GTBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTBP Stock News HeadlinesMarch 27, 2024 | benzinga.comRecap: GT Biopharma Q4 EarningsMarch 26, 2024 | globenewswire.comGT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial ResultsApril 23, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…February 25, 2024 | msn.comGT Biopharma (GTBP) Price Target Increased by 2900.00% to 153.00February 14, 2024 | finance.yahoo.comGTBP Feb 2024 2.500 callFebruary 2, 2024 | finance.yahoo.comGT Biopharma, Inc. (GTBP)February 2, 2024 | msn.comGT Biopharma Announces Reverse Stock Split UpdateFebruary 2, 2024 | benzinga.comGT Biopharma Stock (NASDAQ:GTBP), Short Interest ReportApril 23, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…February 1, 2024 | finance.yahoo.comGT Biopharma, Inc. Announces 1-for-30 Reverse Stock SplitDecember 14, 2023 | markets.businessinsider.comBuy Rating for GT Biopharma: High Efficacy and Expanded Potential in Oncology TherapeuticsDecember 6, 2023 | finance.yahoo.comLeading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of StockholdersDecember 4, 2023 | msn.comGT Biopharma submits IND to FDA for CD33+ leukemia therapyDecember 4, 2023 | finance.yahoo.comGT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ LeukemiaNovember 23, 2023 | markets.businessinsider.comGT Biopharma: Strong Q3 Performance and Promising Pipeline Progression Justify Buy RatingNovember 6, 2023 | finance.yahoo.comGT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNovember 1, 2023 | msn.comGT Biopharma GAAP EPS of -$0.06November 1, 2023 | finance.yahoo.comGT Biopharma Reports Third Quarter 2023 Financial ResultsAugust 24, 2023 | finance.yahoo.comGT Biopharma, Inc. (GTBP) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowAugust 8, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on GT Biopharma (GTBP)August 7, 2023 | finanznachrichten.deGT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2023 Financial ResultsAugust 7, 2023 | finance.yahoo.comGT Biopharma Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comGT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023June 2, 2023 | msn.comHere's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock NowMay 19, 2023 | msn.comAll You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to BuyMay 18, 2023 | msn.comHC Wainwright & Co. Reiterates GT Biopharma (GTBP) Buy RecommendationMay 17, 2023 | msn.comEF Hutton Reiterates GT Biopharma (GTBP) Hold RecommendationSee More Headlines Receive GTBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/15/2021Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GTBP Previous SymbolOTCMKTS:OXISD CUSIPN/A CIK109657 Webwww.gtbiopharma.com Phone(415) 919-4040FaxN/AEmployees2Year Founded1965Price Target and Rating Average Stock Price Target$150.00 High Stock Price Target$150.00 Low Stock Price Target$150.00 Potential Upside/Downside+3,868.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($9.0090) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.84% Return on Assets-69.68% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio2.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.42 per share Price / Book0.70Miscellaneous Outstanding Shares1,380,000Free Float1,243,000Market Cap$5.22 million OptionableOptionable Beta0.59 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael Martin Breen (Age 61)Interim CEO & Executive Chairman Comp: $1.09MMr. Manu Ohri (Age 69)CFO & Secretary Comp: $544.87kDr. Jeffrey S. Miller M.D.Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific AdvisorKey CompetitorsSynaptogenixNASDAQ:SNPXSeelos TherapeuticsNASDAQ:SEELEiger BioPharmaceuticalsNASDAQ:EIGRLongeveronNASDAQ:LGVNPHAXIAM TherapeuticsNASDAQ:PHXMView All Competitors GTBP Stock Analysis - Frequently Asked Questions Should I buy or sell GT Biopharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GTBP shares. View GTBP analyst ratings or view top-rated stocks. What is GT Biopharma's stock price target for 2024? 1 brokerages have issued 1-year price targets for GT Biopharma's stock. Their GTBP share price targets range from $150.00 to $150.00. On average, they expect the company's share price to reach $150.00 in the next year. This suggests a possible upside of 4,009.6% from the stock's current price. View analysts price targets for GTBP or view top-rated stocks among Wall Street analysts. How have GTBP shares performed in 2024? GT Biopharma's stock was trading at $7.65 on January 1st, 2024. Since then, GTBP shares have decreased by 52.3% and is now trading at $3.65. View the best growth stocks for 2024 here. Are investors shorting GT Biopharma? GT Biopharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 8,800 shares, an increase of 79.6% from the March 15th total of 4,900 shares. Based on an average daily volume of 13,200 shares, the short-interest ratio is presently 0.7 days. Approximately 0.7% of the shares of the stock are short sold. View GT Biopharma's Short Interest. When is GT Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our GTBP earnings forecast. How were GT Biopharma's earnings last quarter? GT Biopharma, Inc. (NASDAQ:GTBP) released its earnings results on Thursday, April, 15th. The company reported ($101.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $100.50. When did GT Biopharma's stock split? GT Biopharma's stock reverse split on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of GT Biopharma? Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTBP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
